Munich, Georgia

Ernst Raab


Average Co-Inventor Count = 5.8

ph-index = 1


Location History:

  • Marburg-Dagobertshausen, DE (1993)
  • Marburg, DE (1997)

Company Filing History:


Years Active: 1993-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ernst Raab: Innovator in Cytostatic Anthracycline Derivatives

Introduction

Ernst Raab is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anthracycline derivatives with cytostatic activity. His work has led to the filing of multiple patents that showcase his innovative approach to drug development.

Latest Patents

Ernst Raab holds 2 patents related to semisynthetic diastereomerically pure N-glycidylanthracyclines. His latest patents include a process for the stereoselective preparation of these compounds and their use as cytostatics. The inventions focus on anthracyclines that exhibit cytostatic activity, which are crucial in cancer treatment. The patents detail the chemical structures and potential applications of these compounds, emphasizing their importance in the pharmaceutical industry.

Career Highlights

Throughout his career, Ernst Raab has been associated with Behringwerke Aktiengesellschaft, where he has contributed to various research projects. His expertise in the field of chemistry and pharmaceuticals has positioned him as a key figure in the development of new therapeutic agents. His innovative work continues to influence the direction of research in cytostatics.

Collaborations

Ernst Raab has collaborated with notable colleagues such as Manfred Gerken and Dieter Hoffmann. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical compounds.

Conclusion

Ernst Raab's contributions to the field of pharmaceuticals, particularly in the development of anthracycline derivatives, highlight his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to improving cancer treatment options through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…